PT  - JOURNAL ARTICLE
AU  - CHANG, JOHN WEN-CHENG
AU  - WEI, NIEN-CHIH
AU  - SU, HUNG-JU
AU  - HUANG, JIE-LEN
AU  - CHEN, TSE-CHING
AU  - WU, YI-CHENG
AU  - YU, CHIH-TENG
AU  - HOU, MING-MO
AU  - HSIEH, CHIA-HSUN
AU  - HSIEH, JIA-JUAN
AU  - WU, CHIAO-EN
AU  - CHENG, HSIN-YI
AU  - HSU, TODD
AU  - WANG, TZU-HAO
TI  - Comparison of Genomic Signatures of Non-small Cell Lung Cancer Recurrence between Two Microarray Platforms
DP  - 2012 Apr 01
TA  - Anticancer Research
PG  - 1259--1265
VI  - 32
IP  - 4
4099  - http://ar.iiarjournals.org/content/32/4/1259.short
4100  - http://ar.iiarjournals.org/content/32/4/1259.full
SO  - Anticancer Res2012 Apr 01; 32
AB  - Background: Cancer genomic signatures may vary using different platforms. We compared the differential gene expression in non-small cell lung cancer (NSCLC) between two platforms in order to find the most relevant genomic signatures of tumor recurrence. Materials and Methods: We analyzed gene expression in frozen lung cancer tissue from 59 selected patients who had undergone surgical resection of NSCLC. These patients were divided into two groups: group R, patients who had a tumor recurrence within four years, n=37; group NR, patients who remained disease-free four years following initial surgery, n=22. Each RNA sample was assayed twice using both Affymetrix and Illumina GeneChip. Data were analyzed by principal component analysis and leave-one-out cross-validation. Results: Using the same filtering criteria, 13 genes that were differentially expressed between R and NR were identified by Affymetrix, while 21 genes were identified by Illumina GeneChip. In common, a total of six genes were detected by both systems. Using univariate analysis, four (lipocalin 2, LCN2; parathyroid hormone-like hormone, PTHLH; ras-related protein Rab-38, RAB38; and four jointed box 1, FJX1) of these six genes were associated with survival. A risk score of survival was calculated according to the four-gene expression. There was a significant difference in overall survival between low- and high-risk groups. Conclusion: A four-gene signature is associated with survival among patients with early-stage NSCLC. Further validation of these findings is warranted.